WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New ATC 3rd and 4th levels

List of latest ATC/DDD decisions from the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the decisions should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline (see list). If no objections are received, the new ATC/DDD decisions will be considered final and included in the ATC/DDD Index. In the list final indicates that the date for objection has expired. The year of implementation in the ATC/DDD Index is given in the list.

Please note that the ATC and DDD alterations are only valid and implemented in the coming annual updates of January 1st.

ATC codeATC level nameDeadline for objection to temporary codesImplementation in ATC/DDD index
J06BDAntiviral monoclonal antibodies01.09.20212022
L01EN Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors01.09.20212022
L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES01.09.20212022
L01FACD20 (Clusters of Differentiation 20) inhibitors01.09.20212022
L01FBCD22 (Clusters of Differentiation 22) inhibitors01.09.20212022
L01FCCD38 (Clusters of Differentiation 38) inhibitors01.09.20212022
L01FDHER2 (Human Epidermal Growth Factor Receptor 2) inhibitors01.09.20212022
L01FEEGFR (Epidermal Growth Factor Receptor) inhibitors01.09.20212022
L01FFPD-1/PDL-1 (Programmed cell death protein 1/death ligand 1)
inhibitors
01.09.20212022
L01FGVEGF/VEGFR (Vascular
Endothelial Growth Factor) inhibitors
01.09.20212022
L01FXOther monoclonal antibodies01.09.20212022

Last updated: 2021-05-04